A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...